Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Servant

Showing results (91-100 of 129) with videos related to

Pageof 13
Sort By:
Nature Communications|December 10, 2025
A recurrent pathogenic BRCA2 truncating variant reveals a role for BRCA2-PCAF complex in modulating NF-κB-driven transcriptionAnna Minello, Jesus Gomez-Escudero, Sreerama Chaitanya Sridhara, et al.
Nature|May 14, 2015
Mechanical induction of the tumorigenic β-catenin pathway by tumour growth pressureMaría Elena Fernández-Sánchez, Sandrine Barbier, Joanne Whitehead, et al.
Nature Genetics|May 29, 2019
The bipartite TAD organization of the X-inactivation center ensures opposing developmental regulation of Tsix and XistJoke G van Bemmel, Rafael Galupa, Chris Gard, et al.
Genome Biology|October 24, 2025
Identification of microprotein-coding intronic polyadenylation isoforms and function in genotoxic anticancer drug responseAlexandre Devaux, Iris Tanaka, Quentin Fouilleul, et al.
British Journal of Cancer|August 1, 2024
Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitorsMarie-Paule Sablin, Pierre Gestraud, Sarah Flora Jonas, et al.
NPJ Precision Oncology|July 18, 2024
Metastatic renal cell carcinoma with occult primary: a multicenter prospective cohortNicolas Jacquin, Ronan Flippot, Julien Masliah-Planchon, et al.
Current Oncology (Toronto, Ont.)|October 27, 2023
Patient Derived Xenografts (PDX) Models as an Avatar to Assess Personalized Therapy Options in Uveal Melanoma: A Feasibility StudyFariba Nemati, Leanne de Koning, David Gentien, et al.
The Lancet. Oncology|September 7, 2015
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trialChristophe Le Tourneau, Jean-Pierre Delord, Anthony Gonçalves, et al.
Frontiers in Genetics|June 10, 2014
Bioinformatics for precision medicine in oncology: principles and application to the SHIVA clinical trialNicolas Servant, Julien Roméjon, Pierre Gestraud, et al.
British Journal of Cancer|September 10, 2025
Molecular analysis of lung adenocarcinomas from the SAFIR02-Lung cohort reveals new metastasis-associated copy-number alterations including frequent mutant-specific KRAS-allelic imbalance and identifies CDKN2A homozygous deletions as an independent biomarker of poor prognosisAbderaouf Hamza, Pierre Gestraud, Maryam Karimi, et al.
Pageof 13

Showing results (91-100 of 129) with videos related to

Sort By:
Pageof 13
Nature Communications|December 10, 2025
A recurrent pathogenic BRCA2 truncating variant reveals a role for BRCA2-PCAF complex in modulating NF-κB-driven transcriptionAnna Minello, Jesus Gomez-Escudero, Sreerama Chaitanya Sridhara, et al.
Nature|May 14, 2015
Mechanical induction of the tumorigenic β-catenin pathway by tumour growth pressureMaría Elena Fernández-Sánchez, Sandrine Barbier, Joanne Whitehead, et al.
Nature Genetics|May 29, 2019
The bipartite TAD organization of the X-inactivation center ensures opposing developmental regulation of Tsix and XistJoke G van Bemmel, Rafael Galupa, Chris Gard, et al.
Genome Biology|October 24, 2025
Identification of microprotein-coding intronic polyadenylation isoforms and function in genotoxic anticancer drug responseAlexandre Devaux, Iris Tanaka, Quentin Fouilleul, et al.
British Journal of Cancer|August 1, 2024
Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitorsMarie-Paule Sablin, Pierre Gestraud, Sarah Flora Jonas, et al.
NPJ Precision Oncology|July 18, 2024
Metastatic renal cell carcinoma with occult primary: a multicenter prospective cohortNicolas Jacquin, Ronan Flippot, Julien Masliah-Planchon, et al.
Current Oncology (Toronto, Ont.)|October 27, 2023
Patient Derived Xenografts (PDX) Models as an Avatar to Assess Personalized Therapy Options in Uveal Melanoma: A Feasibility StudyFariba Nemati, Leanne de Koning, David Gentien, et al.
The Lancet. Oncology|September 7, 2015
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trialChristophe Le Tourneau, Jean-Pierre Delord, Anthony Gonçalves, et al.
Frontiers in Genetics|June 10, 2014
Bioinformatics for precision medicine in oncology: principles and application to the SHIVA clinical trialNicolas Servant, Julien Roméjon, Pierre Gestraud, et al.
British Journal of Cancer|September 10, 2025
Molecular analysis of lung adenocarcinomas from the SAFIR02-Lung cohort reveals new metastasis-associated copy-number alterations including frequent mutant-specific KRAS-allelic imbalance and identifies CDKN2A homozygous deletions as an independent biomarker of poor prognosisAbderaouf Hamza, Pierre Gestraud, Maryam Karimi, et al.
Pageof 13